Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratocan is a secreted extracellular matrix proteoglycan, encoded by the *KERA* gene, that binds to keratan sulfate chains and is primarily expressed in the cornea[1][3][4][10]. It belongs to the small leucine-rich proteoglycan (SLRP) family and is essential for the organization of collagen fibrils and maintaining the stromal matrix architecture, thereby ensuring corneal transparency and correct curvature[1][2][3]. Mutations in the *KERA* gene can result in cornea plana 2, a rare autosomal recessive disorder characterized by flattened corneal curvature and impaired vision[1][2][3][4][6][9][10]. There is currently no evidence that keratocan is a direct target of any pharmaceutical drugs or used as a clinical biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratocan (KERA).